BoneScalpel® Featured in the Lecture and Workshop at 9th Congress of the Chinese Association of Orthopedic Surgeons Meeting

FARMINGDALE, N.Y., May 24, 2016 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, today announced that the BoneScalpel was featured in a presentation before the Congress of the Chinese Association of Orthopedic Surgeons Meeting this week in Chengdu, China.  Additionally, Misonix participated in the Master Techniques in Spine Surgery Workshop on May 20, 2016 at the PARTI Center, Huashan Hospital, Fudan University and Chengdu International Exhibition and Convention Center located in Shanghai.  This workshop was jointly planned by the Chinese Association of Orthopaedic Surgeons (CAOS) and The North American Spine Society (NASS).

Professor Feng Li, Director of the Department of Orthopedic Surgery at Tongii Hospital in Wuhan, China presented on his experience with the BoneScalpel in a wide variety of spinal procedures.  The core message in his presentation was that of safety, less blood loss, and greater control in complex surgical procedures of the spine using the BoneScalpel.  This very closely reflects reported data, papers and experiences from around the world.

The cadaveric workshop hosted more than 100 Chinese surgeons and provided for an entire day of hands-on advanced training with the device highlighting its clinical benefits in a number of different complex spine procedures.  In commenting on the program, course Co-Chairman Jeffrey Wang, MD, Chief of the Orthopaedic Spine Service and Co-Director of the USC-University of Southern California Spine Center, and Professor of Orthopaedic Surgery and Neurosurgery, commented, "It was great having Misonix participate in this program. The goal of our international programs are to show novel technologies that can positively influence patient care and provide better outcomes for our patients. Potential game changing technologies like BoneScalpel are important to share with our colleagues around the world and the excitement to try the BoneScalpel in the hands-on lab was great to see."

Scott Ludecker, Senior Vice President of Global Sales & Marketing of Misonix, commented, "We could not be more pleased with the turnout for the cadaveric program this year in Shanghai.  Providing this many surgeons with advanced training on BoneScalpel in a program such as this is unique and we thank the CAOS and NASS for inclusion in this year's program.  Misonix's commitment to global medical education and programs such as this has been a core component to our business.  We look forward to participating in future programs as we further expand our rapidly growing base of surgeon customers who have come to appreciate the clinical benefits of our BoneScalpel technology."

"We continue to be encouraged by the growing interest within the surgical community to participate in opportunities for training on BoneScalpel.  Important labs, such as this past week,  provides an opportunity for potential surgeon customers to learn from expert faculty and Misonix training staff in a very controlled manner.  Whether from the podium with presentations or hands-on training in the lab, BoneScalpel is gaining recognition in the global spinal surgery community. We are very excited about the growth in the use of the BoneScalpel and its recognition by leading surgeons around the world as a unique instrument that provides better outcomes for the surgeon and patient," added Michael A. McManus Jr., President and Chief Executive Officer of Misonix.

About Misonix 
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Logo - http://photos.prnewswire.com/prnh/20160201/328020LOGO

SOURCE Misonix, Inc.

Related Links

http://www.misonix.com